Protara Therapeutics Statistics
Share Statistics
Protara Therapeutics has 38.58M
shares outstanding. The number of shares has increased by 78.57%
in one year.
Shares Outstanding | 38.58M |
Shares Change (YoY) | 78.57% |
Shares Change (QoQ) | 7.13% |
Owned by Institutions (%) | 99.99% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 1,237 |
FTD / Avg. Volume | 0.34% |
Short Selling Information
The latest short interest is 2.48M, so 6.42% of the outstanding
shares have been sold short.
Short Interest | 2.48M |
Short % of Shares Out | 6.42% |
Short % of Float | 6.58% |
Short Ratio (days to cover) | 3.26 |
Valuation Ratios
The PE ratio is -2.44 and the forward
PE ratio is -1.66.
Protara Therapeutics's PEG ratio is
0.06.
PE Ratio | -2.44 |
Forward PE | -1.66 |
PS Ratio | 0 |
Forward PS | 0.6 |
PB Ratio | 0.65 |
P/FCF Ratio | -3.03 |
PEG Ratio | 0.06 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Protara Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.71,
with a Debt / Equity ratio of 0.03.
Current Ratio | 15.71 |
Quick Ratio | 15.71 |
Debt / Equity | 0.03 |
Debt / EBITDA | -0.09 |
Debt / FCF | -0.12 |
Interest Coverage | -11.78 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | $-1,592,714.29 |
Employee Count | 28 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 11.79% in the
last 52 weeks. The beta is 1.72, so Protara Therapeutics's
price volatility has been higher than the market average.
Beta | 1.72 |
52-Week Price Change | 11.79% |
50-Day Moving Average | 3.86 |
200-Day Moving Average | 3.44 |
Relative Strength Index (RSI) | 38.81 |
Average Volume (20 Days) | 362,542 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -49.15M |
Net Income | -44.6M |
EBITDA | -49.15M |
EBIT | -40.42M |
Earnings Per Share (EPS) | -2.17 |
Full Income Statement Balance Sheet
The company has 162.8M in cash and 4.48M in
debt, giving a net cash position of 158.31M.
Cash & Cash Equivalents | 162.8M |
Total Debt | 4.48M |
Net Cash | 158.31M |
Retained Earnings | -244.98M |
Total Assets | 168.56M |
Working Capital | 119.51M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -35.81M
and capital expenditures -63K, giving a free cash flow of -35.87M.
Operating Cash Flow | -35.81M |
Capital Expenditures | -63K |
Free Cash Flow | -35.87M |
FCF Per Share | -1.74 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |